July 14, 2026

Company name:	Mitsui Chemicals, Inc.
Name of representative:	ICHIMURA Satoshi, Representative Director and President (Securities code: 4183; Prime Market of the Tokyo Stock Exchange)
Inquiries:	TAKATAMA Yoshinori, General Manager of Corporate Communications Division (Telephone: +81-3-6880-7500)

(Progress of Disclosure Matters) Notice Regarding Establishment of a New Company in Connection with the Acquisition of Ultradent Products, Inc.

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: ICHIMURA Satoshi; "the Company") hereby announces that, with respect to the "Notice Regarding the Planned Execution of Agreements to Acquire Ultradent Products, Inc." announced on June 12, 2026 (the "Original Disclosure"), the Board of Directors resolved at its meeting held on July 14, 2026 that Mitsui Chemicals America, Inc. (New York, U.S.A.; President: Antonios Grigoriou; "MCA"), a wholly owned subsidiary of the Company, will establish a wholly owned subsidiary (the "Holding Company"), as described below.

In addition, while the Original Disclosure stated that the Holding Company was scheduled to be established in September 2026, the establishment schedule has been changed to July 2026. The Company also announces that the Holding Company will fall under the category of a specified subsidiary of the Company.

1. Purpose of Establishment

As stated in the Original Disclosure, in connection with the acquisition of Ultradent Products, Inc. ("Ultradent") in the United States (the "Acquisition"), the Company will cause MCA to establish the Holding Company in the United States in order to transfer the global headquarters function of the Company's oral care business from Japan to the United States, optimize its global business operating structure, and aim to become a leading company in the oral care field. The Holding Company will acquire and manage Ultradent's shares and business-related assets, and following the completion of the Acquisition, will play a central role in promoting post-merger integration ("PMI") and maximizing integration benefits across the Group.

The Mitsui Chemicals Group's oral care business aims to establish a highly profitable and highly efficient business that will serve as the third pillar of the Life & Healthcare Solutions business. To this end, the Group will maximize the effects of organizational integration and promote growth investments by leveraging the respective products, technologies and regional strengths of Kulzer Group ("Kulzer"), which has strengths in EMEA (Europe, the Middle East and Africa), Ultradent, which has a business foundation in the United States, the world's largest healthcare market, and Sun Medical Co., Ltd. in Japan, among others. In addition, through chemical technologies and Group-wide collaboration, the Group will provide valuable products and services to patients and dental professionals around the world, and aim to transform itself into a solutions provider in the oral care field.

[Positioning of the Holding Company]

(1) At the time of the Acquisition	(2) PMI image
	

2. Overview of the Holding Company

Item		Details
(1) Company name		MC Dental Holdings America, Inc. ("MCDHA")
(2) Head office location		10235 South Jordan Gateway, South Jordan, Utah 84095, U.S.A.
(3) Representative / Title *1		President & CEO: ONO Shingo, who concurrently serves as General Manager of the Oral Care Division of the Life & Healthcare Solutions Business Sector of the Company
(4) Main business activities		To oversee the Company's oral care business as its global headquarters and optimize the business operating structure, among other functions (planned)
(5) Capital stock *2		US$900 million (planned)
(6) Date of establishment		July 24, 2026 (planned)
(7) Major shareholder and shareholding ratio		MCA (100%)
(8) Relationship between the Company and the Holding Company	Capital relationship	To be established as a wholly owned subsidiary of MCA, which is a wholly owned subsidiary of the Company
	Personnel relationship	Employees of the Company are scheduled to serve as representative and director(s) and/or officer(s) of the Holding Company
	Transactional relationship	Not applicable

*1 At the time of establishment, this position will be concurrently held by Antonios Grigoriou, the Company's Representative in the Americas, Business Sector Vice President of the Life & Healthcare Solutions Business Sector, and President of MCA.

*2 The capital of the Holding Company at the time of establishment will be US$100. The capital is planned to be increased to US$900 million by the completion of the Acquisition.

3. Future Outlook

The impact of the establishment of MCDHA on the Company's consolidated financial results is expected to be immaterial. If any matters requiring disclosure arise in the future, the Company will disclose them promptly.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.